Abstract:OBJECTIVE:To investigate the effects of budesonide (BUD) used in an early phase or delayed phase on the airway inflammation and airway remodeling in ovalbumin (OVA) sensitized and challenged mice. METHODS:Forty mice were divided into 5 groups (8 in each group) including group A [ovalbumin (OVA) sensitized/challenged mice], group B (saline sensitized/challenged mice), group C (OVA sensitized/challenged mice treated by BUD in the early phase), group D (OVA-sensitized/challenged mice treated by BUD in the late phase) and group E (OVA-sensitized/challenged mice following saline challenge for 18 days). Mice were sensitized on days 0 and 14 by OVA and challenged from days 24 to 41 by OVA repeatedly to establish a murine model of asthma characterized by airway inflammation and airway remodeling. To assess the effects of BUD on the development of airway remodeling and on established airway remodeling, animals were treated with aerosolized BUD (0.5 mg/ml per day) from day 1 before OVA challenge (group C) and from day 18 following first OVA challenge (group D). The outcome measurements included airway inflammatory indices, eosinophils (EOS) count and amount of collagen deposition around the bronchus, area of airway smooth muscle, the degree of mucus secretion in the lumens and depth of airway smooth muscle (ASM) in different grade bronchus by HE, PAS and Masson's staining. The bronchoalveolar lavage fluids (BALF) were assayed for IL-5 and IFN-gamma levels. RESULTS:In repeatedly OVA-challenged mice (group A), EOS counts in BALF increased significantly [(57.460 +/- 11.060) x 10(4)/ml] when compared with group B [(0.050 +/- 0.020) x 10(4)/ml, P < 0.01]. The IL-5 level increased significantly [(52.9 +/- 2.8) pg/ml vs (16.8 +/- 1.5) pg/ml, < 0.01] and IFN-gamma decreased significantly [(39.5 +/- 3.2) pg/ml vs (63.8 +/- 3.3) pg/ml, < 0.01]. Repeatedly OVA-challenged animals (group A) also developed an increase in EOS counts around bronchus [(1 018 +/- 118)/mm(2)] when compared with group B [(7 +/- 3)/mm(2), < 0.01], goblet cell hyperplasia [(46.0 +/- 5.8)% vs (1.8 +/- 0.5)%, < 0.01] and mucus hypersecretion [(score 2.98 +/- 0.23) vs (score 0.13 +/- 0.06), < 0.01], airway smooth muscle hypertrophy [(30.2 +/- 2.2)/microm(2)/microm vs (13.1 +/- 1.0) microm(2)/microm, < 0.01], enhanced collagen deposition of reticular basement membrane (RBM) [(24.9 +/- 1.3) microm(2)/microm vs (4.3 +/- 0.6) microm(2)/microm, all < 0.01]. Early treatment with BUD significantly reduced EOS counts in BALF [(7.140 +/- 1.250) x 10(4)/ml] as compared with group A [(57.460 +/- 11.060) x 10(4)/ml], < 0.01]. Early BUD treatment also significantly reduced EOS counts around bronchus [(214 +/- 26)/mm(2)], allergen-induced structural changes including goblet cell hyperplasia [(16.1 +/- 2.5)%] and mucus hypersecretion (1.10 +/- 0.15), airway smooth muscle hypertrophy [(14.0 +/- 0.7) microm(2)/microm], and RBM collagen deposition [(12.6 +/- 1.3) microm(2)/microm]. In group E, EOS counts in BALF [(1.250 +/- 0.330) x 10(4)/ml] were decreased significantly when compared with group A (< 0.01), but airway smooth muscle hypertrophy [(32.4 +/- 1.8) microm(2)/microm], and RBM collagen deposition [(22.8 +/- 1.7) microm(2)/microm] showed no reduction as compared with group A (all P > 0.05). Delayed BUD treatment significantly reduced EOS counts in BALF [(0.800 +/- 0.170) x 10(4)/ml], goblet cell hyperplasia [(29.3 +/- 4.3)%] and mucus hypersecretion (1.63 +/- 0.17, < 0.05 or < 0.01), but had no effects on OVA-induced airway smooth muscle hypertrophy [(30.1 +/- 1.8) microm(2)/microm] and RBM collagen deposition [(23.7 +/- 1.4) microm(2)/microm] as compared with group A (P > 0.05). CONCLUSIONS:Early treatment with BUD inhibited the development of airway inflammation of airway remodeling. However, delayed use with BUD inhibited airway inflammation, but only partially reversed airway remodeling in a murine model of asthma.

Dynamic Changes in Airway Hyperresponsiveness As a Result of Allergen and Therapeutic Effects of Budesonide in Rats

The Expression of STAT5b Mrna and IL-4 Mrna of Mononuclearcell in Blood of a Rat Model of Asthma and the Modulatory Effect of Budesonide

Investigation of the Measurement of Murine Airway Hyperresponsiveness and the Therapeutic Effects of Budesonide on Ovalbumin Sensitized and Challenged Mice

Altered Frequency of NK Cells and Treg Cells by Astragalus Polysaccharide Combined with Budesonide in Asthma Model Mice

Effects of Budesonide on Airway Inflammation and Airway Remodeling in the Ovalbumin Sensitized and Challenged Mice

Effects of increasing sensitizing doses of ovalbumin on airway hyperresponsiveness in asthmatic mice

Effects of Ozone Repeated Short Exposures on the Airway/lung Inflammation, Airway Hyperresponsiveness and Mucus Production in a Mouse Model of Ovalbumin-Induced Asthma.

The effects of intranasal budesonide on allergen-induced production of interleukin-5 and eotaxin, airways, blood, and bone marrow eosinophilia, and eosinophil progenitor expansion in sensitized mice.

Effects of Terbutaline and Budesonide on Sputum Cells and Bronchial Hyperresponsiveness In Asthma

The roles of thymic stromal lymphopoietin receptor and its antibody in airway inflammatory response in asthmatic mice

Quantitative CT Metrics for the Prediction of Therapeutic Effect in Asthma.

Comparison of the Roles of House Dust Mite Allergens, Ovalbumin and Lipopolysaccharides in the Sensitization of Mice to Establish A Model of Severe Neutrophilic Asthma

[Effects of Cyclosporin A Aerosol on Airway Hyperresponsiveness in Rats].

Protective Effects of Astragaloside IV Combined with Budesonide in Bronchitis in Rats by Regulation of Nrf2/Keap1 Pathway.

Study Effect of Vitamin D on the Immunopathology Responses of the Bronchi in Murine Model of Asthma

Effects of Budesonide Plus Vitamin AD on Children with Bronchial Asthma and the Effect on Serum IgE and C-reactive Protein

Dexmedetomidine reduces IL-4 and IgE expression through downregulation of theTLR4/NF-κB signaling pathway to alleviate airway hyperresponsiveness in OVA mice

Prevention of allergic airway hyperresponsiveness and remodeling in mice by Astragaliradix Antiasthmatic decoction

[Effect of Exposure to Allergen Through Different Duration on a Rat Asthmatic Model].

The Efficacy of Budesonide-formoterol in Patients with Acute Attacks of Mild-to-moderate Bronchial Asthma: An Observational Study

Dual Effect of Low-Molecular-Weight Bioregulators of Bacterial Origin in Experimental Model of Asthma